

EffiZell

Development of a unique cell culture product for gentle and efficient cell expansion for biopharma manufacturers.

The Project

Gentle, inexpensive and efficient cell expansion is particularly relevant in the field of biopharma production for medium-sized companies and BigPharma. By ensuring high cell quality and thus yield, reducing process steps and using sustainable materials, we want to create an attractive alternative to the previously established cell culture processes. Green Elephant Biotech's novel cell culture systems are based on renewable raw materials and offer a large surface-to-volume ratio through clever geometry. By equipping these cell culture systems with a surface coating developed and patented at the Fraunhofer IZI-BB for the gentle cultivation of adherent cells, additional cell-damaging process steps can be replaced.

The Team

Location: Green Elephant Biotech (GEB) in Gießen & Fraunhofer IZI-BB in Potsdam

Members: Dr. Joel Eichmann (Co-Founder, MD @ GEB), Felix Wollenhaupt (Co-Founder, MD @ GEB), Dr. Lukas Käber (Head of R&D @ GEB), Dr. Katja Uhlig (Group Leader @ IZI-BB)

AHEAD Infos **Batch:** 12 in 2022 **Phase:** 1 **Track:** Licensing

The Business Model

Unique Selling Proposition: Reduction / Simplification of cell culture effort (automation potential)
Increase cell quality (gentle method)

Unfair Advantage: Replacement of invasive process step (enzymatic digestion) and elimination of associated washing steps required in standard cultivation of adherent cells.

Revenue Model: Production

Venture Readiness Level



Technology Readiness Level



The Side Facts

Customer Focus: B2B

Searching For: Pilot customers

Industry Tags: Pharma, Biotech, Cell therapy, Gene therapy

Technology Tags: Biotech, Cell culture, Single-use, Consumables, PLA